PRALIDOXIME, 2%, vial powder + 10ml amp. diluent

STD DINJPRAL2A1S

Valid Article

Former Code(s): DINJZTF0068 DINJZBD0074
The product is supplied (and stored) sterile, it must remain sterile until its use. Sterile = state of being free from all living microorganisms.
4.2 - Specific
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
V03AB04
Anatomical Therapeutic Chemical Classification according to WHOCC
The order of this product needs to be justified and is only acceptable under certain conditions.
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

See Related

Add article to list

   

Add Kit To Wishlist

   

PRALIDOXIME

Therapeutic Action

Cholinesterase reactivator

Antidote to organophosphates which bind to the esteratic site of acetylcholinesterase, which results initially in reversible inactivation of the enzyme.

Indications

Poisoning caused by organic phosphorous pesticides (diazinon, malathion, parathion, sarin...) and by organophosphate chemicals ("nerve gases") used in chemical warfare.

To be administered in combination with atropine injectable.

Some restricted information has been hidden. Sign in to see this information

Instructions for use

Reconstitute the powder vial with the solvent provided.

Administer the reconstituted solution either as:

  • slow IV injection
  • IV infusion in 5% dextrose or 0.9% NaCl
  • IM injection

Dosage :

Adults :

  • initial dose: 2 g as slow IV or IM injection in severe forms (respiratory or neurological distress). Start with 200 to 400 mg in other cases and increase if necessary.
  • maintenance dose: IV infusion of 5-8 mg/kg/h, or repeated injections of 200-400 mg depending on the clinical progress (e.g. every 4 hrs).

Children:

  • initial dose: 40 mg/kg as slow IV (over 15 min) or IM injection in severe forms (respiratory or neurological distress). Start with 20 mg/kg in other cases and increase if necessary.
  • maintenance dose: 10 mg/kg/hour as long as necessary

Administer immediately after poisoning. Pralidoxime has little effect if the delay between intoxication and the start of treatment is greater than 36 hrs.

Administration of pralidoxime must be accompanied by management of vital needs (airway management, respiratory and cardiovascular support), atropinisation and decontamination.

Precautions for Use

The intake of milk or fat promotes the absorption of organophosphates.

Reduce doses in patients with impaired renal function.

Storage

  • Below 25ºC - Protect from sunlight
  • Once opened, use the product immediately.
  • Discard any unused solution.